Fears over black market weight loss drugs as people left seriously ill from counterfeit Ozempic
Austria’s criminal investigation service warned on Monday that fake injection pens may still be in circulation
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Several people were hospitalised in Austria after using suspected fake versions of Novo Nordisk’s diabetes drug Ozempic, the country’s health safety body said, the first report of harm to users as a European hunt for counterfeiters widened.
The patients were reported to have suffered hypoglycaemia and seizures, serious side effects that indicate the product contained insulin instead of Ozempic’s active ingredient semaglutide, the health safety regulator BASG said on Monday.
Austria’s criminal investigation service warned on Monday that fake injection pens may still be in circulation.
The European Medicines Agency (EMA) last week warned about the existence of such pens falsely labelled as Ozempic.
The Danish maker of the drug, Novo Nordisk, had flagged a surge in online offers of counterfeit Ozempic as well as its weight-loss drug Wegovy, both based on semaglutide.
The company, which had been scrambling to boost output to catch up with overwhelming demand, did not immediately respond to a request for comment.
“It appears that this shortage is being exploited by criminal organisations to bring counterfeits of Ozempic to market,” said BASG.
The BASG did not provide an exact number of people harmed by the fake Ozempic, or say how long-lasting the adverse effects would be on their health.
The organisation running the European Union’s Medicines Verification System, which conducts digital surveillance of drugs dispensed by pharmacists, on Tuesday confirmed EMA’s finding that no fakes had emerged in retail pharmacies.
EMA and authorities in Germany and Britain, including prosecutors in southwestern Germany, have been investigating a case where bogus injection pens with German labels in genuine Ozempic packaging were sold from a wholesaler in Austria to Germany, and from there, on to two British wholesalers.
BASG said it would not comment further on the case, to protect the investigation.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments